A diagnosis is often a threshold event. Before the threshold, a person may be told that nothing is wrong or that the signal is too vague to interpret. After the threshold, the system acts. That structure is practical for clinical workflows, but it can obscure the biological motion that happens long before the label appears.
Cytognosis starts from a different premise for research: disease is a trajectory through biological space. The question is not only "what category does this person fit?" It is "where is this state moving, relative to baseline, across which axes, and with what uncertainty?"
Labels compress heterogeneity
Clinical labels can group together people whose underlying mechanisms differ. They can also separate people whose biology is related but whose symptoms present differently. That compression is one reason many complex diseases remain difficult to stratify, study, and treat.
A trajectory model does not discard labels. It places them inside a broader representation. The label becomes one observation about a path, not the whole path.
Time is part of the signal
Single snapshots are easy to store and compare, but disease biology is dynamic. A value matters partly because of where it came from and where it appears to be going. The same measurement can mean different things depending on whether it is stable, returning to baseline, or drifting persistently away from baseline.
What the map enables
A map lets researchers represent continuous variation. It supports similarity search across individuals and cohorts. It allows uncertainty to be attached to a position. It makes it possible to compare axes of deviation instead of only comparing diagnostic groups.
This is why Cytognosis invests in coordinate infrastructure before clinical claims. A map that cannot be inspected, reproduced, and validated would only add another layer of opacity. A map built for open science can become a shared surface for asking better questions.